ArticleThe review of economics and statistics2018
THE LOCAL INFLUENCE OF PIONEER INVESTIGATORS ON TECHNOLOGY ADOPTION: EVIDENCE FROM NEW CANCER DRUGS.
Article in The review of economics and statistics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Association of Quetiapine Overuse Letters With Prescribing by Physician Peers of Targeted Recipients: A Secondary Analysis of a Randomized Clinical Trial.JAMA psychiatry · 2019Trial
- Does access to quality accreditation improve health? - Patient-level evidence from German cancer care.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer.JNCI cancer spectrum · 2025Article
- Hospital Allocation and Racial Disparities in Health Care.The review of economics and statistics · 2024Article
- Geographic disparity in the distribution of cancer clinical trials in the United States and the associated factors.Journal of managed care & specialty pharmacy · 2024Article
- REPRESENTATION AND EXTRAPOLATION: EVIDENCE FROM CLINICAL TRIALSThe quarterly journal of economics · 2024Article
- The diffusion of health care fraud: A bipartite network analysis.Social science & medicine (1982) · 2023Article
- Drug Diffusion Through Peer Networks: The Influence of Industry Payments.American economic journal. Economic policy · 2022Article
- Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.Cancer medicine · 2021Article
- Dynamics of Health Technology Diffusion in the Integrated Care System (DHTDICS): A Development and Validation Study in China.Risk management and healthcare policy · 2021Article
- Patient Characteristics Associated with Receipt of Prescription Weight-Management Medications Among Veterans Participating in MOVE!Obesity (Silver Spring, Md.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Local opinion leaders may play a key role in easing information frictions associated with technology adoption. This paper analyzes the influence of physician investigators who lead clinical trials for new cancer drugs. By comparing diffusion patterns across 21 new cancer drugs, we separate correlated regional demand for new technology from information spillovers. Patients in the lead investigator's region are initially 36% more likely to receive the new drug, but utilization converges within four years. We also find that superstar physician authors, measured by trial role or citation history, have broader influence than less prominent authors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.